SCYNEXIS, Inc. Loans Payable, Current
SCYNEXIS, Inc. (SCYX) had Loans Payable, Current of $34.65 million as of 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities
us-gaap:LoansPayableCurrent · last filed 2023-05-10
- 2023-03-31: Loans Payable, Current $34.65M.
- 2022-12-31: Loans Payable, Current $0.00.
| Period end | Loans Payable, Current |
|---|---|
| 2023-03-31 | $34.65M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $0.00 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |